Home » Stocks » SERA

Sera Prognostics, Inc. (SERA)

Stock Price: $9.15 USD -0.71 (-7.20%)
Updated Jul 27, 2021 4:00 PM EDT - Market closed
Market Cap 279.16M
Revenue (ttm) 30,000
Net Income (ttm) -21.51M
Shares Out 30.51M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 27
Last Price $9.15
Previous Close $9.86
Change ($) -0.71
Change (%) -7.20%
Day's Open 9.90
Day's Range 8.91 - 9.90
Day's Volume 127,814
52-Week Range 8.91 - 15.50

News

Hide News

SALT LAKE CITY, July 14, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker in...

1 week ago - GlobeNewsWire

Sera Prognostics, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

The PreTRM® Test Is Designed to Build a Foundation for Healthy Communities One Baby at a Time

2 months ago - GlobeNewswire

About SERA

Sera Prognostics is a women’s health diagnostic company utilizing our proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. Our vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to dramatically reduce healthcare costs. Our first commercial product, the PreTRM test, is ... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jul 15, 2021
CEO
​ Gregory C. Critchfield, M.D., M.S.
Employees
71
Stock Exchange
NASDAQ
Ticker Symbol
SERA
Full Company Profile

Financial Performance

In 2020, SERA's revenue was $25,000, a decrease of -30.56% compared to the previous year's $36,000. Losses were -$19.85 million, 20.1% more than in 2019.

Financial Statements